Insight Surgery secures $2.5M to deliver faster, safer, and more precise orthopaedic procedures in the US

US surgical teams face challenges balancing better patient outcomes with economic pressures. Even minor delays or complications can impact recovery, hospital costs, and patient satisfaction in orthopaedic procedures. The stakes are high: studies show that nearly one in seven patients is readmitted within 30 days of major surgery, and each additional hour in the operating room can add thousands of dollars to a procedure’s cost.
Insight Surgery platform digitises surgical planning and creates bespoke guides for each operation. This solution aims to reduce operating times and recovery periods while improving precision and lowering complication and readmission rates. Clinical studies have shown that 3D-printed surgical guides can reduce operative time by an average of 23 minutes per case, translating to significant cost savings and improved outcomes.
Insight Surgery, a UK-based personalised surgery startup, just raised $2.5M in Series A funding to expand in the US. Nodenza Venture Partners led the round, following the company’s recent FDA 510(k) clearance for its patient-specific surgical guides. These guides are manufactured using advanced materials like LaserForm Ti and DuraForm ProX PA. These materials offer up to 20 times the strength and 70% thinner profiles than traditional guides, enhancing surgical access and reliability.
Following the Series A round, Insight Surgery aims to deepen its presence across the US and extend its technology’s reach into more hospitals. The company’s growth strategy includes broadening its applications beyond orthopaedics to maxillofacial and oncology procedures, where precision and patient-specific planning are equally vital.
Research indicates that 3D-printed guides are already considered standard of care in complex craniomaxillofacial surgeries, and Insight’s expansion into these fields could further cement its leadership. Its partnerships with top-tier hospitals and surgeons will continue to drive adoption and clinical validation, ensuring that the benefits of personalised surgery reach more patients nationwide.
Insight Surgery was co-founded by CEOHenry Pinchbeck, a Cambridge-educated entrepreneur with a background in life sciences commercialisation. Technical co-founder Peter Tofield, a biomedical engineer, has extensive experience in medical device design and manufacturing. While working on technology spinouts from UK academic institutions, the duo met and saw a shared opportunity to revolutionise orthopaedic surgical planning through digital tools. Their UK-based roots and early exposure to surgical challenges in the NHS inspired the company’s mission to make advanced surgical planning accessible and scalable.
The EmbedMed platform processes patient scan data and provides advanced surgical planning capabilities. Surgeons can digitally simulate procedures and then use the system’s output to receive either virtual planning models or physical surgical guides, typically within 10 working days. The platform’s speed is a key differentiator, as many competitors require significantly longer lead times, which can delay patient care.
These guides are manufactured at Insight’s ISO 13485-certified and FDA-registered facility in Houston, located at the Texas Medical Centre, the world’s largest medical complex. This strategic location enables close collaboration with leading clinicians and rapid feedback for continuous product improvement.
Since launching in the US in 2023, the company has formed strategic partnerships with Ricoh USA and top-tier hospitals, including the Hospital for Special Surgery in New York, University Hospitals of Chicago, University of Florida Health, and UAB in Alabama. These collaborations validate the technology and position Insight Surgery to scale rapidly across the US.
CEO Henry Pinchbeck explained the company’s broader vision, “Our mission is to make advanced surgical planning tools accessible and scalable across the US healthcare system. This investment allows us to accelerate our plan to enable every orthopaedic surgeon in the US to have easy access to personalised surgical devices within surgically meaningful timelines. We’re excited to build on the momentum we’ve already seen with leading clinicians.”
“We’re not just focused on improving surgical precision – we’re focused on doing it in a way that makes financial sense for healthcare systems. By reducing operating time, streamlining workflows, and lowering complication and readmission rates, our technology can help hospitals drive down costs while delivering better care. This investment allows us to scale that impact nationwide.”
The market for personalised surgery is becoming increasingly competitive, with players such as Materialise and 3D Systems offering digital planning and guide production services. The global surgical planning software market is projected to grow from $113.9 million in 2024 to $215.4 million by 2034, while the 3D printed surgical guide market is expected to reach $9.5 billion by 2032.
However, Insight sets itself apart with its vertically integrated platform, fast turnaround times, and deep clinical collaborations. Its Houston facility leverages the latest FDA-cleared materials, producing guides that are stronger, more precise, and tailored to each patient’s unique anatomy.
According to Dr Adam Levine, a leading musculoskeletal oncology surgeon who has used Insight’s technology in the operating theatre, “Insight’s technology makes it possible for me and my colleagues to operate with greater precision and speed, which directly improves outcomes for patients and reduces the likelihood of costly complications. This means fewer revisions, shorter operative times, and faster recoveries for hospitals and providers. It’s a rare example of a surgical innovation that’s both clinically and economically compelling.”
Ross Morton, Managing Partner at Nodenza Venture Partners, shared why the investor led this round: “Insight Surgery is exactly the kind of company we look to back. Disruptive tech, with clear patient benefits, is being delivered now, not tomorrow. And, with the right funding in place, the potential to be the leader in the personalised surgery market.”
“Their platform addresses a real need in orthopaedic surgery by enabling better outcomes via bespoke products. This resonates with surgeons and health systems looking to meet patient demand in personalised surgery. With the support that the Nodenza team can provide, we believe Insight is well-positioned to scale rapidly across the US.”
The fresh capital will help the company open two new manufacturing facilities at hospital sites on the East and West Coasts. Additionally, Insight plans to double its US headcount in the coming months, supporting production and R&D as the company explores integrating AI and machine learning into its planning platform for even greater surgical precision.